The generic deal locks the price. It can't lock the supply.
The pCPA's quiet two-year extension keeps Canada's generic savings flowing to 2028. It also runs straight through the window in which Washington decides whether to tariff the molecules underneath them.
A light-and-sound headset may slow Alzheimer's. Canada's access system, built for molecules, has nowhere to put it.
The 40 Hz idea is real science, contested in the places that matter, with a pivotal trial due mid-2026. The harder question is the one no one else is asking: if it works, Canada's drug-built access pipeline has nowhere to put a device — and no way to pay for it.
pCPA · FormularyCanada blinks first: the generic-semaglutide dam breaks, and the retail channel will not reset to brand
Health Canada cleared two generic semaglutides inside four days. The story isn't the price drop everyone reported — it's that the country just rewired the dispensing economics of its single largest drug class, and the wiring is permanent.
pCPAThe quiet deal that underwrites every pharmacy margin: pCPA and CGPA extend generic pricing to 2028
A two-year extension of a generic-pricing agreement is the least glamorous item of the quarter. It also governs the economics beneath roughly four of every five prescriptions dispensed in Canada.
Specialty distributionThe tariff overhang: a 200% US threat collides with a chronically fragile Canadian supply chain
A US tariff aimed at reshoring pharma manufacturing would land on a Canadian distribution system that is already running 1,500 active shortages on a good day. The channel risk isn't price. It's whether the molecules show up at all.
FormularyOttawa says the quiet part out loud: pharmacare is “set to end,” and the coverage map freezes at 17%
A single line in Question Period did more to define Canada's drug-reimbursement map than the Pharmacare Act itself. The program isn't expanding. It's being quietly bounded — and the boundary is now the story.
BiosimilarsThe private-payer biosimilar gap is the unclaimed margin
Public switching is effectively nationwide. Private plans are still paying originator prices on the same molecules — the most actionable structural inefficiency in the Canadian channel right now.
PMPRBPMPRB sharpens the knife: paper-based hearings signal that price enforcement is finally coming
For most of its 40 years, the federal price watchdog has been a body that rarely bites. A dry procedural consultation suggests that's about to change — and patented list prices that anchor channel economics are the target.
CADTH / INESSSCDA-AMC compresses the clock: a 180-day review quietly reorders launch sequencing
A procedural reform to the reimbursement-review timeline reads like inside baseball. It actually moves the starting gun on every downstream channel event — pCPA negotiation, provincial listing, launch sequencing — earlier by months.
CADTH / INESSS · Specialty distributionA new specialty-infusion lane opens: Gazyva clears CDA-AMC in lupus nephritis
A positive reimbursement recommendation for an infused biologic in a renal-autoimmune indication is a discrete event with an outsized channel signature — it establishes a reimbursement pathway where none existed.
CADTH / INESSSOncology perioperative expansion: Imfinzi wins a conditional public-funding nod in gastric/GEJ
A reimburse-with-conditions recommendation for a durvalumab regimen in resectable gastric cancer extends an immunotherapy franchise into the perioperative setting — and the conditions attached are where the channel economics actually get decided.
pCPApCPA's two-speed queue: the Targeted Negotiation Process formalizes a fast lane
The pCPA has split its negotiation pipeline into complex and non-complex tracks, and the channel-timeline consequences are larger than the procedural framing suggests.
The news is the commodity. The read is the product.
Read every analysis free with an account, ad-supported on the web. The Connector brings that same interpretation — structured, queryable, with the full archive — into your own AI assistant.